FRONT-2 enrolled treatment-naïve and recently diagnosed treatment-experienced wet AMD patients, unlike the ...
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could ...
Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 ...
Training a computer vision model on a 50:50 blend of synthetic and real eye images produces more reliable segmentation of the ...
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm ...
The US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for ONS-5010 (LYTENAVA) ...
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for ...
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial ...
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions ...
Conventional SLT requires gonioscopy-lens visualization; DSLT fires 120 pulses (1.8 mJ, 50 Hz) transsclerally with eye tracking, completing most sessions without contact. At 2 months, mean IOP fell ...
In this podcast, experts Mary Qiu, MD; Paul Singh, MD; and Danica J. Marrelli, OD, FAAO; discuss interventional glaucoma. This more proactive management approach aims to minimize the challenges of ...
Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results